Who Paid My Doc
Dariusz Pierko
Family Medicine Bridgton, ME Doctor of Osteopathy
NPI 1417074188 CMS profile 18678
14 Wyonegonic Rd, Attn Sandy Odgers, Bridgton, ME 04009
General payments
$1,318
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Dariusz Pierko of Bridgton, ME is reported in the CMS Open Payments database as having received $1,318 across 132 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 73rd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $125 | 1 | |
| 2020 | General | $39 | 3 | |
| 2019 | General | $1,154 | 128 |
Beside peers
- Dariusz Pierko
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Dariusz Pierko were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Dariusz Pierko | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,154 | $150 | $41–$543 | $163 |
| 2020 | $39 | $120 | $32–$415 | $114 |
| 2021 | $0 | $137 | $35–$551 | $132 |
| 2022 | $125 | $137 | $37–$512 | $149 |
| 2023 | $0 | $149 | $42–$545 | $160 |
| 2024 | $0 | $156 | $44–$560 | $164 |
| 2025 | $0 | $155 | $45–$549 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 122 drugsPart D claims
5,966
Drug cost
$708,389
Branded share of claims
26.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 85 | $89,760 | |
| Eliquis Apixaban | Brand | 51 | $64,088 | |
| Farxiga Dapagliflozin Propanediol | Brand | 46 | $54,233 | |
| Sublocade Buprenorphine | Brand | 23 | $46,989 | |
| Xarelto Rivaroxaban | Brand | 33 | $43,993 | |
| Januvia Sitagliptin Phosphate | Brand | 34 | $40,877 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 47 | $35,818 | |
| Jardiance Empagliflozin | Brand | 18 | $32,174 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 55 | $27,825 | |
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 124 | $20,756 |
The 10 drugs with the highest cost, of 122 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Records
132 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in Maine
Related records
Family Medicine in Maine
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Maine
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.